Found: 5
Select item for more details and to access through your institution.
Isoniazid Adherence Reduces Mortality and Incident Tuberculosis at 96 Weeks Among Adults Initiating Antiretroviral Therapy With Advanced Human Immunodeficiency Virus in Multiple High-Burden Settings.
- Published in:
- Open Forum Infectious Diseases, 2022, v. 9, n. 7, p. 1, doi. 10.1093/ofid/ofac325
- By:
- Publication type:
- Article
Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women.
- Published in:
- Clinical Infectious Diseases, 2022, v. 74, n. 9, p. 1604, doi. 10.1093/cid/ciab665
- By:
- Publication type:
- Article
Prospective International Study of Incidence and Predictors of Immune Reconstitution Inflammatory Syndrome and Death in People Living With Human Immunodeficiency Virus and Severe Lymphopenia.
- Published in:
- Clinical Infectious Diseases, 2020, v. 71, n. 3, p. 652, doi. 10.1093/cid/ciz877
- By:
- Publication type:
- Article
EFFECTIVENESS OF DOLUTEGRAVIR IN PEOPLE ON RIFAMPIN-BASED TUBERCULOSIS TREATMENT.
- Published in:
- Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 301
- By:
- Publication type:
- Article
Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)—report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group
- Published in:
- PLoS ONE, 2023, v. 17, n. 2, p. 1, doi. 10.1371/journal.pone.0281580
- By:
- Publication type:
- Article